PDS FDA OKs IND Application for Combo to Treat Metastatic Colorectal Cancer

 Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer Institute

Second Versamune® platform candidate targets MUC1-positive solid tumors

U.S. Patent #12,201,685 covering methods of using combinations of the Versamune® platform and various immunocytokines, including PDS01ADC recently issued

https://www.globenewswire.com/news-release/2025/03/13/3042134/37149/en/PDS-Biotech-Announces-FDA-Clearance-of-IND-Application-for-Combination-of-Versamune-MUC1-and-PDS01ADC-to-Treat-Metastatic-Colorectal-Cancer.html